Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Hofseth BioCare ASA Capital/Financing Update 2019

Sep 16, 2019

3622_rns_2019-09-16_5e4dbc3b-1ae6-4ba0-8be0-503395768576.html

Capital/Financing Update

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company" or "HBC") on 2 September 2019, regarding a repair issue with gross proceeds of up to NOK 6 million directed towards eligible shareholders (the "Repair Issue").

The subscription period for the Repair Issue ends today, 16 September 2019 at 16.30 hours (CEST). Subscription rights that are not utilized within the end of the subscription period will lapse automatically and hold no value.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Phone: +47 936 32 966

E-mail: [email protected]

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Palo Alto, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act